Woebot Well being scores $9.5M and extra digital well being fundings

Date:

Share post:



Woebot Well being, maker of an AI-powered psychological well being chatbot, introduced Tuesday it has raised $9.5 million from Leaps by Bayer.

The strategic funding comes about eight months after the corporate stated it had scored $90 million in Collection C funding. Final 12 months, Woebot acquired FDA Breakthrough System Designation for its digital therapeutic treating postpartum despair.

“Woebot Well being’s mission and merchandise are properly aligned with our leaps quantity 5 and 10 to guard the mind and the thoughts, and to rework well being with information,” Dr. Jürgen Eckhardt, head of Leaps by Bayer, stated in a press release.

“With its deep deal with medical proof and distinctive AI-based platform and merchandise, Woebot Well being is forging a brand new frontier in behavioral well being at a crucial time in our world. We’re excited to help endeavors that can make tech-supported steady care a actuality for all.”

Based in 2017, Woebot places its complete elevate at $123.5 million.


OpenLoop, which offers staffing and help to digital well being corporations launching digital care providers, scooped up $8 million in Collection A funding. 

The spherical was led by SpringTide Ventures with participation from ManchesterStory, Subsequent Degree Ventures, Panoramic Ventures, ISA Ventures and a few strategic healthcare syndicates. OpenLoop stated the Collection A brings its complete elevate to about $11 million. 

The startup presents regulatory and authorized help, supplier staffing, telehealth infrastructure, administrative providers and income cycle administration to corporations constructing out digital care providers. It says it should use the funding to develop its tech infrastructure and rent new staffers for its follow administration and income cycle groups.


Prescription digital therapeutic firm metaMe Well being raised $2.2 million in a bridge funding spherical led by Hyde Park Angels with participation from particular person traders.

The corporate will use the funding to arrange for the market launch of Regulora, a prescription digital therapeutic geared toward treating stomach ache related to irritable bowel syndrome in adults. The therapeutic acquired FDA 510(okay) clearance late final 12 months. metaMe stated it plans to launch Regulora within the second half of 2022.

“We’re thrilled to have the help of HPA as we put together for the launch of Regulora,” CEO Tim Rudolphi stated in a press release. “We imagine that Regulora is poised to alter the lives of the tens of millions of Individuals who are suffering from IBS. HPA’s help offers the capital and experience we have to put together for launch and lift our Collection A funding.”



Supply hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Related articles

Patch to Warn of Drug Overdose in Improvement

By Dennis Thompson HealthDay ReporterTUESDAY, Could 17, 2022 (HealthDay Information) -- With the US going through an...

10 Methods The Affected person-Physician Relationship Can Be Improved Simply

This can be a collaborative submit. A great patient-doctor relationship is essential. It helps put sufferers relaxed, figuring...